Navigation Links
Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
Date:5/28/2009

following kidney, liver and heart transplants. According to United Network for Organ Sharing (UNOS), in 2007, 79.3% of kidney transplant recipients were discharged with a Prograf + MMF medication regimen.

The Clinical Studies

The FDA's approval of Prograf + MMF for use in kidney transplant recipients was based on the review of two clinical studies involving approximately 2,000 kidney transplant recipients. A phase III, multi-center, open-label clinical trial was conducted where 424 kidney transplant recipients received Prograf or cyclosporine in combination with MMF, basiliximab induction and corticosteroids. The study reported that the rate for the combined endpoint of biopsy proven acute rejection, graft failure, death and/or lost to follow-up at 12 months in the Prograf/MMF group was similar to the rate in the cyclosporine (CyA)/MMF group. There was, however, an imbalance in mortality at 12 months in those patients receiving Prograf/MMF (4.2%) compared to those receiving CyA/MMF (2.4%), including cases attributed to overimmunosuppression. This study was published in the March 2007 issue of the American Journal of Transplantation.

A second comparative clinical study was the ELITE-Symphony study, supported by Hoffmann La Roche, Inc. This study was a prospective, randomized, open-label, multicenter study in four parallel groups of kidney transplant recipients. The trial randomly assigned 1,589 kidney transplant recipients to receive standard dose CyA, MMF and corticosteroids (CS); or daclizumab induction, MMF and corticosteroids in combination with low-dose CyA, Prograf or sirolimus (Siro). The primary endpoint of the study was renal function, measured by estimated glomerular filtration rates (GFR), at 12 months after transplantation. Acute rejection, graft survival and overall mortality were also assessed as secondary endpoints. This study was published in the December 2007 issue of t
'/>"/>

SOURCE Astellas
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
2. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
3. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
4. CV Therapeutics Statement on Unsolicited Proposal From Astellas
5. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
6. Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)
7. CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
8. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
9. Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program
10. Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
11. Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Dr Jaspreet Singh , Senior Research Officer from ... the 2015 Asian Starch Conference, to be held ... , As an honored ... Starch: A Potential Source for the Creation of Next ... a 528 page text book entitled "Advances in Potato ...
(Date:5/5/2015)... Mass. , May 5, 2015  Blueprint ... closing of its initial public offering of 9,367,708 ... price of $18.00 per share, including shares of ... the underwriters of their option to purchase additional ... offering to Blueprint Medicines were approximately $168.6 million, before ...
(Date:5/5/2015)... 5, 2015  23andMe, Inc., the leading personal genetics ... Research Study in collaboration with Pfizer Inc. The ... erythematosus, more commonly known as lupus, into the study ... effort is also in collaboration with the Lupus Research ... May. Approximately 1.5 million people in the ...
(Date:5/5/2015)... 2015 Research and Markets ... of the "Separation Systems Market in ... Macromolecules which include protein, RNA, DNA ... broken into smaller molecules, during production of ... various advanced systems like centrifugation, liquid chromatography, ...
Breaking Biology Technology:Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2Blueprint Medicines Announces Closing of Initial Public Offering 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2
... 26, 2011 Enanta Pharmaceuticals, Inc. announced ... hepatitis C virus (HCV) inhibitor program, EDP-239, has been ... Interesting Infectious Disease Projects to Watch." EDP-239 was chosen ... NS5A, a clinically-validated target, is a ...
... human energy demands are essential to our future. While sunlight ... we have yet to learn how to capture, transfer and ... chemistry professor Greg Scholes, the answers can be found in ... production often starts with the energy from light being absorbed ...
... of the first laser in 1960 scientists discovered that shining ... color; more specifically, it produced light of exactly twice the ... generation. The green laser pointers in use today ... such a beautiful emerald beam is no easy feat. The ...
Cached Biology Technology:Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch 2Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch 3Nature offers key lessons on harvesting solar power, says U of T chemistry professor 2Stanford engineers create nanoscale nonlinear light source 2Stanford engineers create nanoscale nonlinear light source 3Stanford engineers create nanoscale nonlinear light source 4
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... Acquisition to increase engineering capabilities, client base and,revenues, ... (OTC,Bulletin Board: BMRX), today announced that it has ... LLC, in which bioMETRX can,acquire a controlling interest ... have not yet been finalized., Biometric Solutions ...
... or "interdisciplinary" education evolved in the United States ... 20th century. Integrated education features a student-centered approach ... co-planners of learning experiences. In the early ... incorporate integrated curriculum strategies into primary and secondary ...
... COLLEGE STATION, TX - A new generation has come ... in 1970. For this and future generations, environmental awareness ... Today,s urban children live in environments that offer little ... have to depend on sources such as television and ...
Cached Biology News:bioMETRX, Inc. Signs Deal To Acquire Controlling Interest in Biometric Solutions, LLC 2bioMETRX, Inc. Signs Deal To Acquire Controlling Interest in Biometric Solutions, LLC 3Integrated curriculum enhances academics 2Children's gardening programs grow environmental stewards 2
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
GBL Antibody...
Biology Products: